NCT01803763View on ClinicalTrials.gov

Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Chronic UrticariaChronic Idiopathic UrticariaChronic Spontaneous Urticaria
Interventions
DRUG

Omalizumab (Xolair)

Fixed dose of 300 mg omalizumab is subcutaneously administered in total 4 monthly doses

DRUG

Placebo

Fixed dose of placebo is subcutaneously administered in total 4 monthly doses

Trial Locations (1)

3010

Department of Rheumatology, Clinical Immunology and Allergology, Bern University Hospital, Bern

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Adverse Drug Reactions, Advice and Consulting ADR-AC

UNKNOWN

collaborator

University of Bern

OTHER

collaborator

Novartis

INDUSTRY

lead

Insel Gruppe AG, University Hospital Bern

OTHER

NCT01803763 - Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients | Biotech Hunter | Biotech Hunter